Max Gelman
Max Gelman ties clinical data to commercial consequence, focusing on how late-stage trial results and regulatory decisions reshape the business prospects of new medicines. He reports on the biopharma industry for Endpoints News, with a core focus on drug pipelines, oncology and other specialty areas where science, strategy and market pressure meet.
Oncology pipelines and pivotal trial readouts
Gelman’s coverage concentrates on late-stage drug development, especially oncology programs that are approaching or entering pivotal trials. He frequently builds stories around fresh efficacy and safety data, explaining trial design, primary endpoints and patient populations in clear terms before turning to what those outcomes mean for a company’s portfolio.
Rather than treating a data drop as an isolated milestone, he shows how a Phase 2 or Phase 3 result can shift internal priorities, threaten incumbents or open a new commercial niche. Setbacks receive the same level of attention as wins, with detail on adverse events, pauses or discontinuations and how those problems can ripple through a pipeline or strategy.
Across these pieces he keeps a steady focus on the medium-term stakes: competitive positioning, timelines to filing, and how much room is left in a given indication before the field is saturated.
Antibody-drug conjugates and other next-gen modalities
Within oncology, Gelman spends particular time on antibody-drug conjugates and other next-generation modalities that are drawing heavy investment. His reporting on Merck’s antibody-drug conjugate sac-TMT and its first global Phase 3 win, delivered ahead of internal expectations, is a template for his approach: he walks through the clinical result, locates it within an increasingly crowded modality class, and looks at what it means for the company’s broader ambitions in that space. He often treats individual assets as proof points for larger trends, such as how far companies are willing to push dosing, combinations or new tumor types to secure an edge.
When he covers emerging technologies beyond ADCs, he uses similar framing, showing how technical choices in trial design and target selection feed directly into business risk, differentiation and potential pricing power.
Big pharma strategy, partnerships and pipeline risk
Although his stories are rooted in clinical programs, Gelman consistently connects those programs to big pharma strategy and business outcomes. He tracks how large companies re-balance their portfolios in response to successes and failures, whether that means doubling down on a mechanism, walking away from a class or reshuffling resources between franchises.
Coverage of new readouts routinely includes discussion of looming loss-of-exclusivity cliffs, internal revenue targets or competitive threats that make a given asset more or less central to a company’s future. When collaborations, co-development deals or licensing agreements sit behind a program, he highlights how economics and governance of those relationships shape development decisions.
Across this work he treats business risk as multi-dimensional, blending scientific uncertainty, regulatory scrutiny and market dynamics rather than reducing it to a single financial metric.
Fast-turn industry news with technical clarity
Gelman writes primarily in a fast-turn news format, often filing closely against company announcements or major data events. His stories are concise but technically specific, taking the extra step to spell out what a headline result means in practical terms for clinicians, regulators and investors without resorting to boosterish language.
He regularly weaves in comments from company executives or external experts to test the strength of the narrative a company is presenting against the underlying data. Even on tight timelines, he avoids treating press releases as standalone sources, instead pressing for context on earlier trial phases, competing programs and what still needs to be proven.
The result is coverage that gives industry readers enough scientific and strategic detail to understand why a data point matters, not just that it happened.
4 more business journalists.
Aaron Karp
Aaron Karp is distinct for connecting airline networks, airport infrastructure, air cargo and policy. He is a senior editor at Air Transport World and has covered aviation since 1999. He has also worked as an editor for cargo-focused and daily aviation publications. His real beat is how airlines and airports respond to growth, regulation, trade conditions, sustainability pressures and technology changes. He covers route planning, network development, airport capacity, infrastructure, cargo flows, trade lanes, safety, air traffic control and future technology. He reports through news, features, opinion pieces, briefings and podcasts. He uses data, executive insight and industry conference reporting to explain market changes. His work links cargo metrics and trade policy to carrier strategy, and connects infrastructure and sustainability decisions to resilience, costs and long-term growth.
Adrienne Roberts
Adrienne Roberts is a business journalist at the Detroit Free Press who covers how policy, regulation and corporate decisions affect Michigan’s cannabis market, jobs, universities and health systems. She has a sustained focus on cannabis taxes, licensing, sales, product rules, consumer safety and local tax revenue. She also reports on unemployment, worker protections, corporate settlements, hiring, higher education, student safety, housing, data centers, health care access and economic forecasts. Roberts joined the Detroit Free Press in 2020 after covering automotive retail, dealers and labor issues for The Wall Street Journal. She explains complex business and regulatory changes with data, legal detail and on-the-ground voices. Her stories focus on practical effects for workers, students, consumers and communities, showing both the numbers and the people behind them.
Alex Bronzini-Vender
Alex Bronzini-Vender is a business reporter who focuses on how economic forces and corporate decisions shape specific communities and industries. He covers business for the Washington Monthly, writing reported pieces at the intersection of commerce and public life. His work reflects the magazine’s emphasis on linking markets and money to power, policy, and everyday experience. He treats business not as balance sheets and deals but as choices that affect local realities. In “Fear and Loathing in Palo Alto,” he uses a city tied to the tech sector to examine how a powerful industry influences a community. He grounds his business beat in on-the-ground consequences rather than treating corporate and financial developments in isolation.
Alex DeMarban
Alex DeMarban stands out for tracking major energy projects over time while showing how economic shifts affect local businesses. He reports for the Anchorage Daily News on business, oil and gas, and general assignments. His coverage focuses on Alaska LNG, long-haul energy projects, mining, ports, transportation infrastructure, and the everyday businesses that keep the state running. He examines financing, tax legislation, labor agreements, regulatory approvals, timelines and costs, and connects government and corporate decisions to workers, communities and consumers. He also reports on restaurant closures, grocery stores, breweries, meaderies, parking and trade disputes. His past coverage includes an open-pit mine near the proposed Ambler road, federal port grants and competitive elections. He reports through dollar figures, project details, public records, business owners and affected workers, showing how policy and resource development play out on the ground.